Aspirin use, cancer, and polyps of the large bowel

Suh, Okhee; Mettlin, Curtis; Petrelli, Nicholas J.

doi:10.1002/1097-0142(19930815)72:4<1171::aid-cncr2820720407>3.0.co;2-d

Cited by 244 publications

(66 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…27,28 Other epidemiological studies generally have found consistent dose relationships for both adenoma [29][30][31][32][33] and cancer. 13,29,[34][35][36][37][38] Although short-term use of aspirin appears to reduce risk of adenoma, [1][2][3]32 we observed that an overall reduction in risk of cancer required more than five years of use. However, because we did not collect data on the number of years of aspirin use at study baseline, duration of use was probably somewhat underestimated.…”

Section: Discussionmentioning

confidence: 67%

“…Further studies should examine the potential for a differential effect of aspirin based on anatomic location which may be related to differences in the molecular characteristics of tumors. 41 Although previous studies have demonstrated an inverse relationship between aspirin and colorectal cancer, 7,8,14,29,[35][36][37][38][39][40][42][43][44][45][46][47][48][49][50][51][52][53][54] the present study differs in several important ways. First, because we collected detailed, updated information on aspirin at a range of doses over 18 years of follow-up, we were able to evaluate long-term use across a broad range of intake.…”

Section: Discussionmentioning

confidence: 95%

See 1 more Smart Citation

Aspirin Dose and Duration of Use and Risk of Colorectal Cancer in Men

et al. 2008

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 67%

Section: Discussionmentioning

confidence: 95%

Aspirin Dose and Duration of Use and Risk of Colorectal Cancer in Men

et al. 2008

View full text Add to dashboard Cite

show abstract

“…There was no way to ascertain whether or not those individuals who refused to complete the instrument differed from participants with respect to aspirin use. Nevertheless, previous studies that used the PEDS database and looked at effects of aspirin on variety of cancer sites like ovary, colon, pancreas, breast, nonHodgkin lymphoma and lung 30,32,[68][69][70][71] consistently replicated established epidemiological associations. Moreover, the descriptive characteristics of the subjects (Table I) are consistent with well documented reports in the literature, [10][11][12] suggesting that the results may be generalized to a larger population.…”

Section: Discussionmentioning

confidence: 99%

Regular aspirin use and esophageal cancer risk

Jayaprakash

Menezes

Javle

et al. 2006

Intl Journal of Cancer

View full text Add to dashboard Cite

Given the high mortality rate and the rapidly increasing incidence rate of esophageal carcinoma, chemopreventive agents are highly desirable. Aspirin has been shown to be associated with reduced risk of developing colorectal carcinoma and other cancers. Even though previous studies have shown reduced risk of esophageal cancer associated with aspirin use, results were inconsistent with respect to frequency and duration of use. In this hospital-based case-control study, 163 esophageal cancer cases were compared to 482 age-and sex-matched hospital controls with nonneoplastic conditions. Participants were classified as regular aspirin users if they had taken the drug at least once a week for 6 months. Results suggest that esophageal cancer risk is significantly lower for regular aspirin users compared to nonusers [adjusted odds ratio (aOR) 0.54; 95% confidence interval (CI) 0.36-0.86]. Individuals who used an equivalent of at least 1 aspirin a day ( 7 tablets/week) were half as likely to have been diagnosed with esophageal carcinoma (aOR 0.47; 95% CI 0.26-0.85), and a linear trend was noted with increasing frequency of use (p trend 0.007). Similar protective effects were noted with 20 years of use, whereas no risk reduction was noted with >20 years of use. Consistent reduction in risk associated with aspirin use was noted among both the major histological subtypes, but the protective effect appears to be more pronounced in adenocarcinoma compared to squamous cell carcinoma. Overall, results from the current study suggest that regular aspirin use may be associated with reduced risk of esophageal cancer. ' 2006 Wiley-Liss, Inc.Key words: aspirin; esophageal cancer; histology; chemoprevention; epidemiology The American Cancer Society has estimated that 14,520 new cases of esophageal carcinoma will be diagnosed in the United States (US) in 2005. 1 Worldwide, esophageal carcinoma is the 8th most common cancer, responsible for 462,000 new cancer cases in 2002. 2 The 5-year survival rate for esophageal carcinoma was only 14% in US 1 and 10% in Europe, 3 contributing to its position as the cancer with 3rd worse survival rate in the US 1 and as the 6th most deadly cancer throughout the world. 2 There has been a significant increase in the incidence rate of esophageal carcinoma among US males since the 1970s. 4,5 Several other countries have also noted a sharp increases in esophageal carcinoma, and in some regions, the rate has increased more than for any other malignancy. 6,7 Interestingly, the 2 main histological subtypes, squamous cell carcinoma and adenocarcinoma, differ from each other not only by the site of origin, histology, progression and risk factors, [8][9][10][11][12] but also by opposite trends in incidence over last 2 decades. 13-15 While the absolute incidence of squamous cell carcinoma of esophagus fell by one-third, the incidence of adenocarcinoma had a 6-fold increase, which represents the greatest rate of increase among all major malignancies in the US. 16 Thus, in light of increased incidence rates, late...

show abstract

“…There is substantial evidence of an inverse association between use of nonsteroidal anti-inflammatory drugs (NSAIDs) and the risk of colorectal cancer (Kune et al, 1988;Rosenberg et al, 1991Rosenberg et al, , 1998Thun et al, 1991Thun et al, , 1993Suh et al, 1993;Muscat et al, 1994;Peleg et al, 1994;Schreinemachers et al, 1994;Giovannucci et al, 1995;Smalley et al, 1999;Baron and Sandler, 2000;Coogan et al, 2000;Langman et al, 2000;Rodrigues and Huerta-Alvarez, 2001). A protective effect was initially observed in experimental studies and has been seen in epidemiologic studies of both cohort and casecontrol designs.…”

mentioning

confidence: 99%

Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study

et al. 2003

View full text Add to dashboard Cite

There is increasing evidence of an inverse association between use of nonsteroidal anti-inflammatory drugs (NSAIDs) and risk of colorectal cancer. However, data regarding other cancer sites are limited. Using data from the population-based North Jutland Prescription Database and the Danish Cancer Registry, we compared cancer incidence among 172 057 individuals prescribed nonaspirin NSAIDs with expected incidence (based on county-specific cancer rates) during a 9-year study period. A total of 6081 incident cancer cases were diagnosed among NSAID users vs 5722 expected (standardised incidence ratio (SIR) 1.1, 95% confidence interval (CI)1.0 -1.1). The SIRs for colon and rectal cancer among persons who obtained 10 or more prescriptions were 0.7 (95% CI 0.6 -0.9) and 0.6 (95% CI 0.4 -0.9), respectively. Similarly, reduced risk estimates were found for stomach (SIR 0.7, 95% CI 0.4 -1.1) and ovarian cancer (SIR 0.7, 95% CI 0.4 -1.0). Standardised incidence ratios for other cancers among those with 10 or more prescriptions tended to be close to 1.0, except for lung, kidney, and prostate cancers with SIRs of 1.3 (95% CI 1.1 -1.6), 1.4 (95% CI 0.9 -2.1), and 1.6 (95% CI 1.3 -2.0), respectively. We found protective associations of NSAIDs against colon, rectal, stomach, and ovarian cancer. Reasons for the increased risk for some cancer sites are not clear.

show abstract

Aspirin use, cancer, and polyps of the large bowel

Cited by 244 publications

References 25 publications

Aspirin Dose and Duration of Use and Risk of Colorectal Cancer in Men

Aspirin Dose and Duration of Use and Risk of Colorectal Cancer in Men

Regular aspirin use and esophageal cancer risk

Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study

Contact Info

Product

Resources

About